Cargando…

P04-02. Increased breadth and potency of the neutralizing antibody response among dually-HIV-1-infected individuals

Detalles Bibliográficos
Autores principales:	Powell, RL, Kinge, T, Nyambi, P
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767804/ http://dx.doi.org/10.1186/1742-4690-6-S3-P30

Ejemplares similares

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus
por: Mayr, LM, et al.
Publicado: (2012)

P04-14. Sequential HIV-1 isolates from infected individuals reveals emergence of neutralization sensitive HIV-1 strains in the course of infection
por: Nyambi, PN, et al.
Publicado: (2009)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

P04-25. Exposure of HIV-1 pseudovirus to soluble CD4 increases the breadth of neutralization with sera from macaques immunized with recombinant glycoproteins
por: Davis, D, et al.
Publicado: (2009)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

Genetic variability and drug resistance mutations in HIV-1 infected individuals on HAART or drug naïve in Limbe, Cameroon
por: Agyingi, L, et al.
Publicado: (2012)

The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission
por: Chaillon, A, et al.
Publicado: (2012)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

Sequential exposure to specific antibody escape mutations may program neutralization breadth during subtype A HIV-1 infection
por: Murphy, MK, et al.
Publicado: (2012)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
por: Holt, Graham T., et al.
Publicado: (2023)

Heterologous neutralization breadth persists despite B-lymphocyte dysfunction in chronic HIV-1 infection
por: Murphy, MK, et al.
Publicado: (2012)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation
por: Crooks, Ema T., et al.
Publicado: (2018)

P04-34. Identification of 4E10-like antibodies in plasma of an HIV-1 CRF02_AG infected patient with broad neutralizing activity using peptide phage libraries
por: Dieltjens, T, et al.
Publicado: (2009)

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth
por: Chukwuma, Valentine U., et al.
Publicado: (2018)

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies
por: Webb, Nicholas E., et al.
Publicado: (2015)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

P04-43. Neutralizing antibody responses against conformational envelope epitopes in early HIV-1 infection
por: Bar, KJ, et al.
Publicado: (2009)

Antibody engineering for increased potency, breadth and half-life
por: Sievers, Stuart A., et al.
Publicado: (2015)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

Native envelope-based immunogens derived from critical timepoints in the development of breadth elicit rapid neutralizing antibodies in rabbits
por: Malherbe, DC, et al.
Publicado: (2012)

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
por: van Dorsten, Rebecca T., et al.
Publicado: (2021)

Rational modification of an HIV-1 gp120 results in enhanced neutralization breadth when used as a DNA prime
por: Wallace, A, et al.
Publicado: (2012)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

Refined identification of neutralization-resistant CRF02_AG viruses and their sensitivity to anti-MPER neutralizing antibodies
por: Jacob, RA, et al.
Publicado: (2012)

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency
por: Frumento, Nicole, et al.
Publicado: (2022)

P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells
por: Todd, CA, et al.
Publicado: (2009)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

P04-27. Monoclonal neutralizing antibodies inhibit HIV-1 transfer from immature dendritic cells to human primary CD4 T-lymphocytes
por: Xu, K, et al.
Publicado: (2009)

P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections
por: Njai, HF, et al.
Publicado: (2009)

P04-02 Are Older Adults Adhering to the Strength Component of the Physical Activity Guidelines?
por: Gluchowski, Ashley, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hcc8d2u492dm4b2gl9ml45t3qp